Antibiotic Stewardship Is Undermining the Economics of Drug Development
Antibiotics are indispensable medicines, but their commercial model is breaking down, argues the Financial Times’ Aanu Adeoye: they take decades and more than $1bn to develop, yet responsible use requires that sales be kept low. As drug resistance drives more than 1mn deaths a year and large companies cut their pipelines, advocates are pushing subscription payments that reward access rather than volume, alongside greater public funding for development.
Financial Times·Aug 10, 2026·3 min read
